Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve...

Benzinga · Dec 20 21:03

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve Statistical Significance'

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve...

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve Statistical Significance'

Risk Disclaimer